more

Neogen (NEOG)

(Real Time Quote from BATS)

$16.56 USD

+0.23 (1.41%)

Updated Jul 22, 2024 03:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

Top 30% (76 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

HEXO (HEXO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on December 15,2022

HEXO (HEXO) delivered earnings and revenue surprises of -250% and 19.23%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Neogen (NEOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research Published on December 13,2022

Neogen (NEOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEOGPositive Net Change

Will Healthy Top-Line Growth Buoy Jabil (JBL) Q1 Earnings?

by Zacks Equity Research Published on December 13,2022

Backed by solid demand in key end markets, diligent execution of operational plans and skillful management of supply chain dynamics, Jabil (JBL) is likely to record healthy fiscal first-quarter revenues.

Neogen's (NEOG) Synergize Disinfectant Now Widely Available

by Zacks Equity Research Published on November 18,2022

Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.

Neogen (NEOG) Down 13.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research Published on October 27,2022

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEOGPositive Net Change

Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips

by Zacks Equity Research Published on October 07,2022

Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.

Neogen (NEOG) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research Published on September 27,2022

Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.51%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

Neogen (NEOG) Launches Test for Detection of Cashew Allergen

by Zacks Equity Research Published on September 20,2022

Neogen's (NEOG) new quantitative test shows a high level of specificity to very low levels of cashew protein (down to 0.2 ppm).

medical

Neogen (NEOG) Finalizes Food Safety Business Merger With 3M

by Zacks Equity Research Published on September 06,2022

The combination of Neogen (NEOG) and 3M's Food Safety division will capitalize on the ongoing growth trends in sustainability, food safety and supply chain integrity.

Phibro Animal Health (PAHC) Q4 Earnings Lag Estimates

by Zacks Equity Research Published on August 24,2022

Phibro (PAHC) delivered earnings and revenue surprises of -10% and 0.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research Published on July 29,2022

Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up

by Zacks Equity Research Published on July 29,2022

Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.